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allowing for potential early detection and real-time monitoring of disease progression. The presence of 
CTCs in patients with metastatic cutaneous head and neck squamous cell carcinoma (cHNSCC) has not 
been evaluated. Results: CTCs were detected in eight of ten patients with regional metastatic cHNSCC 
(80%; range 1-44 cells/9 mL blood). CTMs were detected in three of ten patients (30%, range 1-4 cells/9 
mL blood). Methods: Preoperative blood samples from ten patients with nodal metastases from 
cutaneous squamous cell carcinomas (cSCC) were analyzed using the IsoFluxTM System for the 
detection and enumeration of CTCs and circulating tumour microemboli (CTMs). Conclusions: For the 
first time CTCs have been detected in patients with nodal metastases from cHNSCC. Further work is 
required to understand their prognostic significance and potential to directly influence clinical practice. 
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AbstrAct
Background: Circulating tumour cells (CTCs) are increasingly being used in the 
surveillance of cancer, allowing for potential early detection and real-time monitoring 
of disease progression. The presence of CTCs in patients with metastatic cutaneous 
head and neck squamous cell carcinoma (cHNSCC) has not been evaluated. 
Results: CTCs were detected in eight of ten patients with regional metastatic 
cHNSCC (80%; range 1–44 cells/9 mL blood). CTMs were detected in three of ten 
patients (30%, range 1–4 cells/9 mL blood). 
Methods: Preoperative blood samples from ten patients with nodal metastases 
from cutaneous squamous cell carcinomas (cSCC) were analyzed using the IsoFluxTM 
System for the detection and enumeration of CTCs and circulating tumour microemboli 
(CTMs). 
Conclusions: For the first time CTCs have been detected in patients with nodal 
metastases from cHNSCC. Further work is required to understand their prognostic 
significance and potential to directly influence clinical practice.
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IntroductIon
Australia has the highest incidence of skin cancer 
worldwide, with two in every three Australians developing 
this debilitating disease in their lifetime. Australians are 
four times more likely to develop skin cancer than any 
other form of cancer [1, 2]. Non-melanoma skin cancer 
(NMSC) accounts for over 430,000 new cases each year; 
with 138,000 (20–25%) being squamous cell carcinoma 
(cSCC) [2, 3]. In 2010 alone, there were 445 deaths as a 
result of NMSC, predominately SCC [4]. 
UV radiation is the most significant risk factor 
for cSCC, with the majority of NMSCs located on sun-
exposed areas of the body, particularly the head and neck 
(70%) [1, 5]. cSCC accounts for 20% of all head and neck 
malignancies [6]. 
Treatment of primary lesions includes surgical 
resection, with the addition of adjuvant radiation therapy 
in advanced disease [7]. Currently, adjuvant chemotherapy 
is employed infrequently outside of a trial setting. Despite 
aggressive first line treatment, approximately 5% of cSCC 
cases develop nodal metastases [7]. Whilst relatively 
uncommon, 70% of metastases occur within the first 12 
months following treatment of the primary lesion, with a 
poor prognosis and 5-year overall survival rate of 11% in 
patients with distant metastases [7–10]. 
The early identification of patients at higher 
risk for metastatic spread would help rationalise the 
need for surveillance. Currently, other than traditional 
histopathologic assessment [11], little is understood about 
the potential for metastasis in cSCC.
Carcinomas spread by lymphatic and/or vascular 
infiltration giving rise to circulating tumour cells (CTCs) 
that are shed from the primary tumour [12]. These CTCs 
may exist individually or as microemboli, are readily 
detectable in the peripheral blood and are increasingly 
being used in surveillance in breast, lung, colorectal 
(CRC) and prostate cancer [13]. Subpopulations of 
tumours may have the ability to enter the vascular space 
by mesenchymal transition (Epithelial Mesenchymal 
Transition). Once in the vascular space, tumour cells 
have the opportunity to metastasize to distant sites 
(Mesenchymal Epithelial Transition). The detection of the 
CTCs is a snapshot of this process.  As noted by Grisanti 
[14] CTCs have the potential to provide ‘real-time’ 
monitoring acting as ‘liquid biopsies’. CTC estimation 
may allow real-time monitoring of disease progression or 
reoccurrence and earmark some patients for a change or 
reintroduction of treatment. No studies have as yet focused 
on CTCs as markers for primary or metastatic cSCC. This 
pilot study aimed to preoperatively identify the presence 
of CTCs in patients with nodal metastases from cSCC in 
the head and neck prior to surgery. 
results
A summary of patient characteristics and results is 
provided in Table 1. All patients had previously undergone 
primary tumour resection and had no evidence of distant 
metastatic disease (M0). The IsoFluxTM System was able to 
detect the presence of CTCs in eight of ten patients (80%) 
with cell counts ranging from 1–44 in 9 mL of blood. 
In addition, CTC microemboli clusters (CTMs) were 
detected in three patients (30%), with the highest CTC 
and CTM counts attributed to the same patient. All ten 
patients were treated with curative intent by surgery, and 
eight of ten received adjuvant radiotherapy. Two patients 
succumbed to their disease within the study period. Both 
of these patients had undetectable CTCs and CTMs at the 
time of blood collection. 
dIscussIon
Detectable CTCs have shown implications for 
disease-free survival, overall survival, risk of local 
reoccurrence and risk of metastases in subgroups of other 
solid tumour groups [15]. However no studies have as yet 
focused on CTCs as markers for primary or metastatic 
disease in patients with cSCC. This is the first study to 
examine the presence of CTCs in metastatic cSCC. 
CTCs were identified in eight of ten patients with 
metastatic cSCC using the IsoFluxTM System. We also 
identified circulating tumour microemboli clusters (CTM) 
in three of ten patients. 
Numerous prospective studies have now shown 
a significant association between CTCs and worsening 
metastatic disease, with baseline CTCs acting as strong 
predictors of decreased survival, independent of other 
factors in breast, prostate and colorectal cancer [13]. 
Notably, Jatana [15] demonstrated improved disease-free 
survival in patients with no detectable CTCs in mucosal 
HNSCC. However, in another study, the absence of CTCs 
preoperatively did not necessarily portend a favourable 
outcome in mucosal HNSCC [16]. These authors also 
reported that the only patient (of 16) where no CTCs were 
identified later succumbed to locoregional and distant 
metastatic disease. Interestingly, in our series, there has 
been no correlation between the presence of CTCs and 
patient outcome in the early stages of follow-up. Indeed, 
during the 12-month follow-up period, both patients 
who died (5 months and 8 months post surgery) had no 
recordable CTCs in their preoperative blood sample. Both 
patients had recurrent post radiotherapy disease at the time 
of CTC sampling.  
Whilst we were successful in detecting CTCs, the 
levels detected were quite small in comparison to other 
studies [15]. As noted by Grisanti [14], this may reflect 
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a genuine low count due to the extremely rare nature of 
CTCs in the blood (estimations of 1 in 100 million to 1 
in one billion blood cells). Alternatively, it may represent 
a falsely low count as a result of the absence of Ep-Cam 
and cytokeratin expression on CTCs displaying greater 
mesenchymal morphology [14]. 
Notably, an additional patient enrolled in the study 
was excluded from analysis due to deviation from the 
experimental protocol because blood was collected intra-
operatively. This collection produced interesting results 
with this patient having much higher CTCs/CTMs counts 
detected (86 and 25, respectively). These findings echo 
those of previous animal models which have shown 
correlation between disseminated cancer cells as a result 
of surgical manipulation of tumour, and is paralleled by 
human studies which have displayed increased counts 
of CTCs intraoperatively compared to pre- and post-
operative counts in surgical removal of colorectal liver 
metastases [17, 18]. Once again, this highlights the effect 
of surgery on CTC number, although the significance of 
this is elusive.
We have identified the presence of Ep-CAM and 
cytokeratin expressing cells in the circulation of patients 
with metastatic cSCC. A broadening of CTC markers in 
a positive selection model using mesenchymal and novel 
biomarkers may show higher levels, and may add to our 
understanding of the metastatic process in cSCC. As cSCC 
is the most common malignancy with metastatic potential, 
the ability to identify the small percentage of patients 
where metastases occur would have enormous public 
health implications, particularly in regions with high 
solar exposure. The establishment of CTCs as markers for 
metastatic disease also has the potential to directly inform 
clinical practice by early identification of recurrence and 
the development of individualized treatment pathways for 
patients with high-risk disease. 
MAterIAls And Methods
Patient selection
Ethics approval was obtained from the UOW/
ISLHD Human Research Ethics Committee (HE14/397). 
Inclusion criteria were patients who were candidates for 
surgical treatment of metastatic cSCC affecting the lymph 
nodes of the parotid and/or neck.  Eleven patients were 
enrolled, with one patient excluded from analysis due to a 
major deviation from the experimental protocol.
blood collection
Peripheral blood samples of 9mL were collected and 
drawn into anti-coagulant K3 EDTA coated tubes (Vacuette 
455036; Greiner Bio-One, Interpath Services, VIC, 
Australia) at the time of cannulation immediately pre-
operatively. Blood samples were kept at room temperature 
and processed within 24 hours of collection, using the 
IsoFluxTM System according to manufactures instructions 
and protocol established by Harb [19]. 
sample preparation and ctc isolation
White cell fraction (WCC) was isolated using 
LeucoSep tubes (Greiner Bio-One, Interpath Services, 
VIC, Australia) prepared with 15.2 mL of Ficoll-Paque 
PLUS (GE Healthcare, NSW, Australia), recovered, then 
res-suspended in phosphate-buffered saline (PBS) binding 
buffer. Pre-conjugated immunomagnetic beads (with 
Anti-EpCAM antibodies; CTC Enrichment kit Fluxion 
Biosciences Inc.) were added and the sample incubated on 
a rotator at 4°C for 1.5 hours. Samples were loaded into 
the microfluidic cartridge of the IsoFluxTM System and 
processed for 45 minutes, with magnetically labelled target 
cells captured, isolated and recovered for further processing. 
table 1: Patient summary and circulating tumour cell and microemboli results
treatment
Patient Age sex Pathology nodal 
stage 
histopathology
grade
ctc 
count
ctM 
count
surgery radiation 
therapy
1 85 M cSCC N2b G3 4 2 Yes Adjuvant
2 67 M cSCC N2a G3 0 0 Yes Adjuvant
3 69 M cSCC N2a G3 19 0 Yes Adjuvant
4 77 M cSCC N2a G3 14 1 Yes Adjuvant
5 62 M cSCC N2a G3 44 4 Yes Adjuvant
6 77 M cSCC N1 G3 14 0 Yes Adjuvant
7 88 M cSCC N2b G3 1 0 Yes Prior
8 78 M cSCC N1 G2 4 0 Yes Prior
9 54 M cSCC N2b G1 1 0 Yes Adjuvant
10 66 M cSCC N3 G3 0 0 Yes Adjuvant
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ctc enumeration and imaging
Recovered cells were fixed (PBS containing 1.8% 
formaldehyde), washed and blocked with 10% normal 
donkey serum, then stained with anti-CD45 antibody 
(CTC Enumeration Kit, Fluxion Biosciences, Inc.), Cy3-
conjugated secondary antibody, and permeabilised with 
0.1% Triton X-100. Following this, cells were further 
stained with FITC conjugated anti-cytokeratin antibody 
(CK; CTC Enumeration Kit, Fluxion Biosciences Inc.), 
mounted with Hoechst 33342 (Mounting Media; CTC 
Enrichment Kit, Fluxion Biosciences Inc.), transferred to 
a SensoPlate Glass-Bottom Multiwell Plate (Grenier Bio-
One, Interpath Services, VIC, Australia) and stored in 4° 
for up to 2 weeks for imaging. As per protocol, cells were 
counted as CTCs if they were CK+, and CD45–, nucleated, 
and morphologically intact. Imaging was performed using 
an inverted Olympus IX71 microscope (Olympus Australia 
Pty. Ltd., Victoria, Australia) and Proscan II automatic 
scanning (Prior Scientific Inc., Massachusetts, USA). 
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